Skip to content
OUTBACK Trial with Linda Mileshkin episode artwork

Jun 18, 2021 28 min

OUTBACK Trial with Linda Mileshkin

from IJGC Podcast Hosted by BMJ Group

Linda Mileshkin (@Mileshkin / @anzgog) In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Linda Mileshkin to discuss the OUTBACK Trial. Dr. Mileshkin is the Deputy Director of Medical Oncology at the Peter MacCallum Cancer Centre and a board member of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG). She is a clinician researcher with a particular interest in gynaecological cancer and cancer of unknown primary (CUP). Highlights - Adjuvant chemotherapy with carboplatin and paclitaxel chemotherapy given after standard chemoradiation to women with locally advanced cervical cancer did not improve survival or relapse rates and should not be given. - There is a major unmet need to improve outcomes and access to treatment for women with cervical cancer, as this is a major cause of death and suffering worldwide, most notably in LMICs. - International cooperation is needed to complete international clinical trials in cervical cancer so that we can robustly answer important questions about how to treat this disease.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

OUTBACK Trial with Linda Mileshkin

0:00 28:01

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of IJGC Podcast?

This episode is 28 minutes long.

When was this IJGC Podcast episode published?

This episode was published on June 18, 2021.

Can I download this IJGC Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.